Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies

Journal of Clinical Neuroscience

Volumn 21, Issue 11, 2014, Pages 1835-1846

  Broadley, Simon A ^a,b   Barnett, Michael H ^c   Boggild, Mike ^d   Brew, Bruce J ^e   Butzkueven, Helmut ^f   Heard, Robert ^g   Hodgkinson, Suzanne ^h   Kermode, Allan G ^i,r   Lechner Scott, Jeannette ^j   Macdonell, Richard A L ^k   Marriott, Mark ^f   Mason, Deborah F ^l   Parratt, John ^c   Reddel, Stephen W ^c   Shaw, Cameron P ^m   Slee, Mark ⁿ   Spies, Judith ^c   Taylor, Bruce V ^o   Carroll, William M ⁱ   Kilpatrick, Trevor J ^o   King, John ^f   McCombe, Pamela A ^p   Pollard, John D ^c   Willoughby, Ernest ^q   more..

^a GRIFFITH UNIVERSITY   (Australia)

^b GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d TOWNSVILLE HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g University of Sydney   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^j UNIVERSITY OF NEWCASTLE   (Australia)

^k AUSTIN HEALTH   (Australia)

^l CHRISTCHURCH HOSPITAL   (New Zealand)

^m DEAKIN UNIVERSITY   (Australia)

ⁿ FLINDERS UNIVERSITY   (Australia)

^o UNIVERSITY OF TASMANIA   (Australia)

^p UNIVERSITY OF QUEENSLAND   (Australia)

^q AUCKLAND CITY HOSPITAL   (New Zealand)

^r MURDOCH UNIVERSITY   (Australia)

more..

Author keywords

Evidence based medicine; Guideline; Multiple sclerosis; Review; Treatment

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; FINGOLIMOD; GLATIRAMER; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; PLACEBO; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; ALOPECIA; AMENORRHEA; ANEMIA; ATRIOVENTRICULAR BLOCK; AUSTRALIA; BACKACHE; BLOOD DYSCRASIA; BRADYCARDIA; BRONCHITIS; CANCER RISK; CARDIOTOXICITY; CARDIOVASCULAR RISK; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ECHOCARDIOGRAPHY; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INJECTION SITE NECROSIS; LEUKEMIA; LEUKOPENIA; LIVER FIBROSIS; LIVER TOXICITY; LUNG TOXICITY; MACULAR EDEMA; MORTALITY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEW ZEALAND; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PREMATURE OVARIAN FAILURE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; REVIEW; RISK REDUCTION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADULT; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; DISEASE COURSE; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE; EXPERIMENTAL THERAPY; PRACTICE GUIDELINE; TREATMENT OUTCOME; TRENDS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; AUSTRALIA; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MITOXANTRONE; MULTIPLE SCLEROSIS; NEW ZEALAND; THERAPIES, INVESTIGATIONAL; TREATMENT OUTCOME;

EID: 84908373559     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.01.016     Document Type: Review

References (231)

1. A. Compston, and A. Coles Multiple sclerosis Lancet 372 2008 1502 1517
2. W.T. Mayr, S.J. Pittock, and R.L. McClelland Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000 Neurology 61 2003 1373 1377
3. R.H. Roxburgh, S.R. Seaman, and T. Masterman Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity Neurology 64 2005 1144 1151
4. D.G. Brunet, W.M. Hopman, and M.A. Singer Measurement of health-related quality of life in multiple sclerosis patients Can J Neurol Sci 23 1996 99 103
5. Access Economics Pty Ltd., Acting positively: strategic implications of the economic costs of MS in Australia: Multiple Sclerosis Research Australia; 2005.
6. S. Naito, N. Namerow, and M.R. Mickey Multiple sclerosis: association with HL-A3 Tissue Antigens 2 1972 1 4
7. International Multiple Sclerosis Genetics Consortium, Welcome Trust Case Control Consortium 2, and S. Sawcer Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis Nature 476 2011 214 219
8. International Multiple Sclerosis Genetics Consortium (IMSGC), A.H. Beecham, and N.A. Patsopoulos Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis Nat Genet 45 2013 1353 1360
9. R.M. Lucas, A.M. Hughes, and M.L. Lay Epstein-Barr virus and multiple sclerosis J Neurol Neurosurg Psychiatry 82 2011 1142 1148
10. K.L. Munger, L.I. Levin, and B.W. Hollis Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis JAMA 296 2006 2832 2838
11. K.L. Munger, J. Bentzen, and B. Laursen Childhood body mass index and multiple sclerosis risk: a long-term cohort study Mult Scler 19 2013 1323 1329
12. A.E. Handel, A.J. Williamson, and G. Disanto Smoking and multiple sclerosis: an updated meta-analysis PLoS One 6 2011 e16149
13. B. Hemmer, S. Cepok, and S. Nessler Pathogenesis of multiple sclerosis: an update on immunology Curr Opin Neurol 15 2002 227 231
14. I.E. Ormerod, D.H. Miller, and W.I. McDonald The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study Brain 110 1987 1579 1616
15. J.H. Noseworthy, C. Lucchinetti, and M. Rodriguez Multiple sclerosis N Engl J Med 343 2000 938 952
16. G.P. Rice The natural history of secondary progressive multiple sclerosis: observations from the London study group Mult Scler 8 2002 81 82
17. D.A. Cottrell, M. Kremenchutzky, and G.P. Rice The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis Brain 122 1999 625 639
18. B.G. Weinshenker, B. Bass, and G.P. Rice The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course Brain 112 1989 1419 1428
19. Y.C. Wang, L. Meyerson, and Y.Q. Tang Statistical methods for the analysis of relapse data in MS clinical trials J Neurol Sci 285 2009 206 211
20. O. Gray, and H. Butzkueven Measurement of disability in multiple sclerosis Neurol Asia 13 2008 153 156
21. R.A. Bermel, E. Fisher, and J.A. Cohen The use of MR imaging as an outcome measure in multiple sclerosis clinical trials Neuroimaging Clin N Am 18 2008 687 701
22. I.J. van den Elskamp, B. Boden, and V. Dattola Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis Neuroradiology 52 2010 875 881
23. Product Information Search Page. Australian Governement, 2013. Available from: https://www.ebs.tga.gov.au/ [accessed 02/05/2013, 2013].
24. Pharmaceutical Benefits Scheme. Australian Government, 2013. Available from: http://www.pbs.gov.au/pbs/home [accessed 02/05/2013, 2013].
25. G. Giovannoni Promising emerging therapies for multiple sclerosis Neurol Clin 29 2011 435 448
26. F. Khan, B. Amatya, and L. Turner-Stokes Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis Neurol Res Int 2011 2011 740505
27. Marie P, Lubbock M. Lectures on Diseases of the Spinal Cord. London: Sydenham Society; 1895; London. p. 134-6, 53.
28. W. Crecelius Uber antimonbehandlung der multiple Sklerose Deutsche med Wchnschr 54 1928 1332 1334
29. A.R. Cushny Textbook of Pharmacology and Therapeutics 5th ed. 1910 Lea & Febiger Philadelphia
30. N.D. Compston Disseminated sclerosis; assessment of the effect of treatment on the course of the disease Lancet 265 1953 271 275
31. J.W. Stephenson Diathermy in the treatment of multiple sclerosis Physical Therapy 44 1926 336 339
32. G.L. Dreyfus, and K. Mayer Vier jahne malariabehandlung der multiplen Sklerose Deutsche Z Nervenheilkd 111 1929 68 98
33. R.M. Brickner Quinine therapy in cases of multiple sclerosis over a five year period Arch Neurol Psychiatry 33 1935 1235 1254
34. C. Foix, J.A. Chavany, and M. Levy Les injections intraveineuses de salicylate de soude dans le traitement de la sclérose en plaques Rev Neurol 33 1926 429 431
35. E.F. Buzzard The treatment of disseminated sclerosis: a suggestion Lancet 117 1911 98
36. H. Oppenheim Text-book of nervous diseases for physicians and students 1911 Otto Schulze & Co Edinburgh
37. D. Firth The case of Augustus d'Est 1948 Cambridge University Press Cambridge, England
38. J. Purves-Stewart A specific vaccine treatment of disseminated sclerosis J Nerv Ment Dis 1 1930 560 564
39. E.A. Carmichael The Aetiology of Disseminate Sclerosis: some criticisms of recent work, especially with regard to the "Spherula Insularis" Proc R Soc Med 24 1931 591 606
40. T.J. Putnam, L.V. Chiavacci, and H. Hoff Results of treatment of multiple sclerosis with dicoumarin Arch Neurol Psychiatry 57 1947 1 13
41. D. McAlpine, N.D. Compston, and C.E. Lumsden Multiple sclerosis 1955 E & S Livingstone Edinburgh
42. B.T. Horton, H.P. Wagener, and J.A. Aiat Treatment of multiple sclerosis by the intravenous administration of histamine JAMA 124 1944 800 801
43. T. Ebina, A. Sato, and K. Umezu Treatment of multiple sclerosis with anti-measles cow colostrum Med Microbiol Immunol 173 1984 87 93
44. B.L. Bayard, and M.A. James Hyperimmune bovine colostrum inefficacious as multiple sclerosis therapy in double-blind study J Am Diet Assoc 87 1987 1388 1390
45. B.G. Weinshenker, B. Bass, and S. Karlik An open trial of OKT3 in patients with multiple sclerosis Neurology 41 1991 1047 1052
46. L. Kappos, E.W. Radu, and L. Bernasconi Treatment of multiple sclerosis with 15 +/- deoxyspergualin. Design of a controlled study with close MRI-monitoring Schweiz Arch Neurol Psychiatr 144 1993 198 201
47. H. Fukaura, S.C. Kent, and M.J. Pietrusewicz Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients J Clin Invest 98 1996 70 77
48. D.A. Hafler, S.C. Kent, and M.J. Pietrusewicz Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis Ann N Y Acad Sci 835 1997 120 131
49. J. Lycke, B. Svennerholm, and E. Hjelmquist Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study J Neurol 243 1996 214 224
50. J.E. Friedman, J.B. Zabriskie, and C. Plank A randomized clinical trial of valacyclovir in multiple sclerosis Mult Scler 11 2005 286 295
51. E. Bech, J. Lycke, and P. Gadeberg A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS Neurology 58 2002 31 36
52. B.W. van Oosten, F. Barkhof, and L. Truyen Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 Neurology 47 1996 1531 1534
53. D.P. Gold, R.A. Smith, and A.B. Golding Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide J Neuroimmunol 76 1997 29 38
54. B.W. van Oosten, M. Lai, and S. Hodgkinson Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial Neurology 49 1997 351 357
55. J.D. Bowen, S.H. Petersdorf, and T.L. Richards Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis Clin Pharmacol Ther 64 1998 339 346
56. P.A. Calabresi, N.S. Fields, and H.W. Maloni Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS Neurology 51 1998 289 292
57. J.H. Noseworthy, P. O'Brien, and B.J. Erickson The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis Neurology 51 1998 1342 1352
58. A.M. Rostami, R.A. Sater, and S.J. Bird A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis Mult Scler 5 1999 198 203
59. TTNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. he Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999;53:457-65.
60. L. Kappos, G. Comi, and H. Panitch Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group Nat Med 6 2000 1176 1182
61. B. Bielekova, B. Goodwin, and N. Richert Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand Nat Med 6 2000 1167 1175
62. I.L. Tan, G.J. Lycklama à Nijeholt, and C.H. Polman Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials Mult Scler 6 2000 99 104
63. H. Wiendl, O. Neuhaus, and L. Kappos Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment Nervenarzt 71 2000 597 610
64. J.A. Frank, N. Richert, and B. Lewis A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients Mult Scler 8 2002 24 29
65. N.L. Sicotte, S.M. Liva, and R. Klutch Treatment of multiple sclerosis with the pregnancy hormone estriol Ann Neurol 52 2002 421 428
66. D.T. Wade, C.A. Young, and K.R. Chaudhuri A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis J Neurol Neurosurg Psychiatry 73 2002 246 249
67. D.T. Wade, P. Makela, and P. Robson Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients Mult Scler 10 2004 434 441
68. A. Conte, C.M. Bettolo, and E. Onesti Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis Eur J Pain 13 2009 472 477
69. M. Bennett, and R. Heard Hyperbaric oxygen therapy for multiple sclerosis Cochrane Database Syst Rev 1 2004 CD003057
70. J. Feng, T. Misu, and K. Fujihara Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis Mult Scler 10 2004 494 498
71. H.A. Pershadsingh Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 13 2004 215 228
72. U. Baumhackl, L. Kappos, and E.W. Radue A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis Mult Scler 11 2005 166 168
73. J. Couzin Drug discovery. Magnificent obsession Science 307 2005 1712 1715
74. Fieschi C, Andersen O, Markowitz C, et al. A phase II randomised, double-blind, placebo-controlled study to evaluate the preliminary efficacy and safety of abatacept, a selective co-stimulation modulator, in patients with relapsing-remitting multiple sclerosis. In: 15th Meeting of the European Neurological Society; 2005 18-25 Jun 2005; Vienna.
75. S. Sriram, S.Y. Yao, and C. Stratton Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS J Neurol Sci 234 2005 87 91
76. T. Wesselius, D.J. Heersema, and J.P. Mostert A randomized crossover study of bee sting therapy for multiple sclerosis Neurology 65 2005 1764 1768
77. V. Yadav, G. Marracci, and J. Lovera Lipoic acid in multiple sclerosis: a pilot study Mult Scler 11 2005 159 165
78. G. Burke, A. Cavey, and P.M. Mathews The evaluation of a novel "goat serum" therapy (Aimspro) in multiple sclerosis J Neurol Neurosurg Psychiat 76 2006 1326
79. K.G. Warren, I. Catz, and L.Z. Ferenczi Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment Eur J Neurol 13 2006 887 895
80. M.S. Freedman, A. Bar-Or, and J. Oger A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS Neurology 77 2011 1551 1560
81. A.T. Clucas, A. Shah, and Y.D. Zhang Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715 Clin Pharmacokinet 46 2007 757 766
82. F. Fazekas, F.D. Lublin, and D. Li Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial Neurology 71 2008 265 271
83. D. Pöhlau, H. Przuntek, and M. Sailer Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study Mult Scler 13 2007 1107 1117
84. H. Garren, W.H. Robinson, and E. Krasulová Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis Ann Neurol 63 2008 611 620
85. A. Minagar, J.S. Alexander, and R.N. Schwendimann Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial Arch Neurol 65 2008 199 204
86. R.L. Schnaar, and H.H. Freeze A "glyconutrient sham" Glycobiology 18 2008 652 657 [discussion 658-63]
87. B.M. Segal, C.S. Constantinescu, and A. Raychaudhuri Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study Lancet Neurol 7 2008 796 804
88. Y. Zhang, L.M. Metz, and V.W. Yong Pilot study of minocycline in relapsing-remitting multiple sclerosis Can J Neurol Sci 35 2008 185 191
89. S.A. Broadley, D. Vanags, and B. Williams Results of a phase IIa clinical trial of an anti-inflammatory molecule, chaperonin 10, in multiple sclerosis Mult Scler 15 2009 329 336
90. B. Loftus, B. Newsom, and M. Montgomery Autologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies Clin Immunol 131 2009 202 215
91. D. Karussis, H. Shor, and J. Yachnin T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial PLoS One 7 2012 e50478
92. G. Giovannoni, G. Comi, and S. Cook A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis N Engl J Med 362 2010 416 426
93. N. Sharafaddinzadeh, A. Moghtaderi, and D. Kashipazha The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial Mult Scler 16 2010 964 969
94. B.A. Cree, E. Kornyeyeva, and D.S. Goodin Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis Ann Neurol 68 2010 145 150
95. H.P. Hartung, and B.C. Kieseier Atacicept: targeting B cells in multiple sclerosis Ther Adv Neurol Disord 3 2010 205 216
96. J. Wang, Y. Xiao, and M. Luo Statins for multiple sclerosis Cochrane Database Syst Rev 12 2011 CD008386
97. C.P. Kamm, M. El-Koussy, and S. Humpert Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial J Neurol 259 2012 2401 2413
98. M. Farinotti, L. Vacchi, and S. Simi Dietary interventions for multiple sclerosis Cochrane Database Syst Rev 12 2012 CD004192
99. O. Torkildsen, S. Wergeland, and S. Bakke ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial Arch Neurol 69 2012 1044 1051
100. E.J. van Zuuren, Z. Fedorowicz, and E. Pucci Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients Cochrane Database Syst Rev 12 2012 CD009903
101. A.L. Traboulsee, K.B. Knox, and L. Machan Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study Lancet 383 2013 138 145
102. Biogen Idec Australia Pty Ltd., Product Information - Avonex. Australia: TGA; 28 Jul 2009.
103. Biogen Idec NZ Ltd., Data Sheet - Avonex. Auckland, NZ: Medsafe; 22 Aug 2012.
104. Merck Serono Australia Pty Ltd., Product Information - Rebif. Australia: TGA; 15 Aug 2012.
105. Bayer Australia Limited. Product Information - Betaferon. Australia: TGA; 5 Nov 2010.
106. Bayer New Zealand Limited. Data Sheet - Betaferon. Auckland, NZ: Medsafe; 9 Aug 2010.
107. CSL Biotherapies (NZ) Limited. Data Sheet - Copaxone. Auckland, NZ: Medsafe; 1 Feb 2012.
108. CSL Limited. Product Information - Copaxone. Australia: TGA; 10 Apr 2012.
109. Biogen Idec Australia Pty Ltd., Product Information - Tysabri. Australia: TGA; 26 Nov 2010.
110. Biogen Idec NZ Ltd., Data Sheet - Tysabri. Auckland, NZ: Medsafe; 21 Nov 2012.
111. Novartis New Zealand Limited. Data Sheet - Gilenya. Auckland, NZ: Medsafe; 3 Sep 2012.
112. Novartis Pharmaceuticals Australia Pty Limited. Product Information - Gilenya. Australia: TGA; 11 Oct 2012.
113. Sanofi-Aventis Australia Pty Ltd., Product Information - Aubagio. Australia: TGA; 14 Nov 2012.
114. Biogen Idec Australia Pty Ltd., Product Information - Tecfidera. Australia: TGA; 21 Aug 2013.
115. Genzyme Corporation. Prescibing Information - Campath. US: FDA; 19 Sep 2007.
116. K.A. Buzzard, S.A. Broadley, and H. Butzkueven What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis? Int J Mol Sci 13 2012 12665 12709
117. M. Rollinghoff, J. Schrader, and H. Wagner Effect of azathioprine and cytosine arabinoside on humoral and cellular immunity in vitro Clin Exp Immunol 15 1973 261 269
118. A. Aldinucci, T. Biagioli, and C. Manuelli Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA/6-MP J Neuroimmunol 218 2010 28 35
119. G.W. Ellison, L.W. Myers, and M.R. Mickey A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis Neurology 39 1989 1018 1026
120. D.E. Goodkin, R.C. Bailly, and M.L. Teetzen The efficacy of azathioprine in relapsing-remitting multiple sclerosis Neurology 41 1991 20 25
121. C. Milanese, L. La Mantia, and A. Salmaggi Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results Ital J Neurol Sci 9 1988 53 57
122. C. Milanese, L. La Mantia, and A. Salmaggi A double blind study on azathioprine efficacy in multiple sclerosis: final report J Neurol 240 1993 295 298
123. A. Ghezzi, M. Di Falco, and C. Locatelli Clinical controlled randomized trial of azathioprine in multiple sclerosis R.E. Gonsette, P. Delmotte, Recent advances in multiple sclerosis therapy 1989 Elsevier Amsterdam 345 346
124. I. Casetta, G. Iuliano, and G. Filippini Azathioprine for multiple sclerosis Cochrane Database Syst Rev 4 2007 CD003982
125. L. Massacesi, A. Parigi, and A. Barilaro Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging Arch Neurol 62 2005 1843 1847
126. L. La Mantia, N. Mascoli, and C. Milanese Azathioprine. Safety profile in multiple sclerosis patients Neurol Sci 28 2007 299 303
127. C. Confavreux, P. Saddier, and J. Grimaud Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study Neurology 46 1996 1607 1612
128. J.M. van den Reek, P.P. van Lümig, and M. Janssen Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases J Eur Acad Dermatol Venereol 28 2012 27 33
129. N. Putzki, S. Knipp, and T. Ramczykowski Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis Mult Scler 12 2006 363 366
130. J.R. Bertino The mechanism of action of the folate antagonists in man Cancer Res 23 1963 1286 1306
131. O. Gray, G.V. McDonnell, and R.B. Forbes Methotrexate for multiple sclerosis Cochrane Database Syst Rev 2 2004 CD003208
132. D.E. Goodkin, R.A. Rudick, and S. VanderBrug Medendorp Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis Ann Neurol 37 1995 30 40
133. H. Montaudié, E. Sbidian, and C. Paul Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity J Eur Acad Dermatol Venereol 25 2011 12 18
134. F. Rondon, O. Mendez, and N. Spinel Methotrexate-induced pulmonary toxicity in psoriatic arthritis (PsA): case presentation and literature review Clin Rheumatol 30 2011 1379 1384
135. L. La Mantia, C. Milanese, and N. Mascoli Cyclophosphamide for multiple sclerosis Cochrane Database Syst Rev 1 2007 CD002819
136. O.R. Hommes, and H.L. Weiner Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire J Neurol Sci 223 2004 65 67
137. K. Nozaki, and N. Abou-Fayssal High dose cyclophosphamide treatment in Marburg variant multiple sclerosis A case report J Neurol Sci 296 2010 121 123
138. P. Perini, and P. Gallo Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis J Neurol 250 2003 834 838
139. D.E. Gladstone, R. Peyster, and E. Baron High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis: 2-year follow-up (investigational new drug No. 65863) Am J Ther 18 2011 23 30
140. P. Perini, M. Calabrese, and M. Tiberio Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study J Neurol 253 2006 1034 1040
141. A.C. Allison, and E.M. Eugui Mycophenolate mofetil and its mechanisms of action Immunopharmacology 47 2000 85 118
142. E.M. Frohman, G. Cutter, and G. Remington A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis Ther Adv Neurol Disord 3 2010 15 28
143. G.M. Remington, K. Treadaway, and T. Frohman A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS) Ther Adv Neurol Disord 3 2010 3 13
144. M. Etemadifar, M. Kazemi, and A. Chitsaz Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study J Res Med Sci 16 2011 1 5
145. M.L. Ritter, and L. Pirofski Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity Transpl Infect Dis 11 2009 290 297
146. L. Michel, S. Vukusic, and J. De Seze Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients J Neurol Neurosurg Psychiatry 85 2014 279 283
147. D. Baker, J.K. O'Neill, and A.N. Davison Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone Clin Exp Immunol 90 1992 124 128
148. E. Millefiorini, C. Gasperini, and C. Pozzilli Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome J Neurol 244 1997 153 159
149. G. Edan, D. Miller, and M. Clanet Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria J Neurol Neurosurg Psychiatry 62 1997 112 118
150. H.P. Hartung, R. Gonsette, and N. König Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial Lancet 360 2002 2018 2025
151. H. Krapf, S.P. Morrissey, and O. Zenker Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial Neurology 65 2005 690 695
152. E. Le Page, E. Leray, and G. Taurin Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients J Neurol Neurosurg Psychiatry 79 2008 52 56
153. C. Buttinelli, A. Clemenzi, and G. Borriello Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up Eur J Neurol 14 2007 1281 1287
154. E. Le Page, E. Leray, and G. Edan Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study Mult Scler 17 2011 867 875
155. S. De Castro, D. Cartoni, and E. Millefiorini Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis J Clin Pharmacol 35 1995 627 632
156. S.S. Kim, J.R. Lee, and B.C. Jee Use of hormonal protection for chemotherapy-induced gonadotoxicity Clin Obstet Gynecol 53 2010 740 752
157. L. Michel, Y. Foucher, and S. Vukusic Increased risk of multiple sclerosis relapse after in vitro fertilisation J Neurol Neurosurg Psychiatry 83 2012 796 802
158. E. Cocco, C. Sardu, and P. Gallo Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study Mult Scler 14 2008 1225 1233
159. S. Goffette, V. van Pesch, and J.L. Vanoverschelde Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone J Neurol 252 2005 1217 1222
160. D. Brassat, C. Recher, and E. Waubant Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS Neurology 59 2002 954 955
161. J.J. Marriott, J.M. Miyasaki, and G. Gronseth Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 74 2010 1463 1470
162. R.G. Ghalie, E. Mauch, and G. Edan A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis Mult Scler 8 2002 441 445
163. A. Pielen, S. Goffette, and V. Van Pesch Mitoxantrone-related acute leukemia in two MS patients Acta Neurol Belg 108 2008 99 102
164. Ellis RJ, Brown S, Boggild M. Therapy related acute leukaemia with mitoxantrone: 4 years on, what is the risk and can it be limited? Association of British Neurologists joint meeting with the Royal College of Physicians; 23-24 Oct 2013; London.
165. C.E. Markowitz Interferon-beta: mechanism of action and dosing issues Neurology 68 2007 S8 S11
166. L.D. Jacobs, D.L. Cookfair, and R.A. Rudick Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol 39 1996 285 294
167. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504.
168. R.A. Rudick, D.E. Goodkin, and L.D. Jacobs Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology 49 1997 358 363
169. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-61.
170. D.K. Li, and D.W. Paty Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis Ann Neurol 46 1999 197 206
171. D.W. Paty, and D.K. Li Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group Neurology 43 1993 662 667
172. J.H. Simon, L.D. Jacobs, and M. Campion Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group Ann Neurol 43 1998 79 87
173. Placebo-controlled multicentre randomised trial of interferon beta-1b intreatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998;352:1491-7.
174. L. La Mantia, L. Vacchi, and C. Di Pietrantonj Interferon beta for secondary progressive multiple sclerosis Cochrane Database Syst Rev 1 2012 CD005181
175. L.D. Jacobs, R.W. Beck, and J.H. Simon Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group N Engl J Med 343 2000 898 904
176. L. Kappos, C.H. Polman, and M.S. Freedman Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes Neurology 67 2006 1242 1249
177. L. Kappos, M.S. Freedman, and C.H. Polman Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial Lancet Neurol 8 2009 987 997
178. E.U. Walther, and R. Hohlfeld Multiple sclerosis: side effects of interferon beta therapy and their management Neurology 53 1999 1622 1627
179. C.H. Polman, D.H. Miller, and W.I. McDonald Treatment recommendations for interferon-beta in multiple sclerosis J Neurol Neurosurg Psychiatry 67 1999 561 564
180. Y.D. Fragoso, E.R. Frota, and J.S. Lopes Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis Clin Neuropharmacol 33 2010 312 316
181. P. Rieckmann, P. O'Connor, and G.S. Francis Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis Drug Saf 27 2004 745 756
182. R.A. Rudick, N.A. Simonian, and J.A. Alam Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology 50 1998 1266 1272
183. H.P. Hartung, M.S. Freedman, and C.H. Polman Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome Neurology 77 2011 835 843
184. S. Zarkou, J.L. Carter, and K.E. Wellik Are corticosteroids efficacious for preventing or treating neutralizing antibodies in multiple sclerosis patients treated with beta-interferons? A critically appraised topic Neurologist 16 2010 212 214
185. M. Ravnborg, K. Bendtzen, and O. Christensen Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis Mult Scler 15 2009 323 328
186. A. Langer-Gould, H.H. Moses, and T.J. Murray Strategies for managing the side effects of treatments for multiple sclerosis Neurology 63 2004 S35 S41
187. D.S. Goodin, A.T. Reder, and G.C. Ebers Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial Neurology 78 2012 1315 1322
188. A. Shirani, Y. Zhao, and M.E. Karim Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis JAMA 308 2012 247 256
189. D.S. Goodin, A.T. Reder, and G. Cutter Treatment with interferon beta for multiple sclerosis JAMA 308 2012 1627
190. M. Trojano, P. Russo, and A. Fuiani The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis Mult Scler 12 2006 578 585
191. K. Ellerman, and S. Brostoff A suppressor cell line that prevents the adoptive transfer of EAE in Lewis rats Ann N Y Acad Sci 540 1988 364 366
192. M.K. Racke, and A.E. Lovett-Racke Glatiramer acetate treatment of multiple sclerosis: an immunological perspective J Immunol 186 2011 1887 1890
193. V. Skihar, C. Silva, and A. Chojnacki Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate Proc Natl Acad Sci U S A 106 2009 17992 17997
194. F. Blanchette, and O. Neuhaus Glatiramer acetate: evidence for a dual mechanism of action J Neurol 255 2008 26 36
195. D.D. Mikol, F. Barkhof, and P. Chang Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial Lancet Neurol 7 2008 903 914
196. P. O'Connor, M. Filippi, and B. Arnason 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study Lancet Neurol 8 2009 889 897
197. D. Teitelbaum, C. Webb, and M. Bree Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer Clin Immunol Immunopathol 3 1974 256 262
198. K.P. Johnson, B.R. Brooks, and J.A. Cohen Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group Neurology 45 1995 1268 1276
199. O. Khan, P. Rieckmann, and A. Boyko Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis Ann Neurol 73 2013 705 713
200. M.B. Bornstein, A. Miller, and S. Slagle A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis N Engl J Med 317 1987 408 414
201. Y. Ge, R.I. Grossman, and J.K. Udupa Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment Neurology 54 2000 813 817
202. G. Comi, M. Filippi, and J.S. Wolinsky European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group Ann Neurol 49 2001 290 297
203. G. Comi, V. Martinelli, and M. Rodegher Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial Lancet 374 2009 1503 1511
204. L. La Mantia, L.M. Munari, and R. Lovati Glatiramer acetate for multiple sclerosis Cochrane Database Syst Rev 5 2010 CD004678
205. G.P. Rice, H.P. Hartung, and P.A. Calabresi Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale Neurology 64 2005 1336 1342
206. T.A. Yednock, C. Cannon, and L.C. Fritz Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin Nature 356 1992 63 66
207. B.S. Bochner, F.W. Luscinskas, and M.A. Gimbrone Jr. Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules J Exp Med 173 1991 1553 1557
208. M.E. Hemler, M.J. Elices, and C. Parker Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions Immunol Rev 114 1990 45 65
209. R.R. Lobb, and M.E. Hemler The pathophysiologic role of alpha 4 integrins in vivo J Clin Invest 94 1994 1722 1728
210. C.H. Polman, P.W. O'Connor, and E. Havrdova A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910
211. R.A. Rudick, W.H. Stuart, and P.A. Calabresi Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 2006 911 923
212. A. Langer-Gould, S.W. Atlas, and A.J. Green Progressive multifocal leukoencephalopathy in a patient treated with natalizumab N Engl J Med 353 2005 375 381
213. A. Antonsson, A.C. Green, and K.A. Mallitt Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians J Gen Virol 91 2010 1849 1853
214. J.M. Kean, S. Rao, and M. Wang Seroepidemiology of human polyomaviruses PLoS Pathog 5 2009 e1000363
215. P.A. Calabresi, G. Giovannoni, and C. Confavreux The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL Neurology 69 2007 1391 1403
216. D.S. Im Linking Chinese medicine and G-protein-coupled receptors Trends Pharmacol Sci 24 2003 2 4
217. Y. Anada, Y. Igarashi, and A. Kihara The immunomodulator FTY720 is phosphorylated and released from platelets Eur J Pharmacol 568 2007 106 111
218. H. Chi Sphingosine-1-phosphate and immune regulation: trafficking and beyond Trends Pharmacol Sci 32 2011 16 24
219. V. Brinkmann FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system Br J Pharmacol 158 2009 1173 1182
220. J. Chun, and H.P. Hartung Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis Clin Neuropharmacol 33 2010 91 101
221. S.R. Schwab, J.P. Pereira, and M. Matloubian Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients Science 309 2005 1735 1739
222. K. Chiba FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors Pharmacol Ther 108 2005 308 319
223. M.A. Morris, D.R. Gibb, and F. Picard Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720 Eur J Immunol 35 2005 3570 3580
224. L. Kappos, E.W. Radue, and P. O'Connor A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis N Engl J Med 362 2010 387 401
225. J.A. Cohen, F. Barkhof, and G. Comi Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis N Engl J Med 362 2010 402 415
226. F. Fazekas, T. Berger, and T.H. Fabjan Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group Wien Med Wochenschr 162 2012 354 366
227. B. Khatri, F. Barkhof, and G. Comi Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study Lancet Neurol 10 2011 520 529
228. FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod). FDA; 2013. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm366529.htm [accessed 1 Nov 2013, 2013].
229. A. Uccelli, F. Ginocchio, and G.L. Mancardi Primary varicella zoster infection associated with fingolimod treatment Neurology 76 2011 1023 1024
230. J.N. Ratchford, K. Costello, and D.S. Reich Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod Neurology 79 2012 2002 2004
231. FDA Drug Safety Communication: safety review of a reported death after the first dose of multiple sclerosis drug Gilenya (fingolimod); 2011. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm284240.htm [accessed 8 Aug 2013, 2013].